다발성 골수종

83개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved83 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

CAR-T cells Infusion (CAR-T cells Infusion)

Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

CAR-T treatment (CAR-T treatment)

Multiple Myeloma; Relapsed/Refractory · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 1

CAR19-BCMA dual-target CAR-T (CAR19-BCMA dual-target CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 1

CAR19BCMA-T cells (CAR19BCMA-T cells)

Relapsed or Refractory Plasma Cell Neoplasms; Lymphomas/Leukemias With Plasmacytic Differentiation · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART-138 cells (CART-138 cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundación Pública Andaluza para…Phase 2

CARTemis-1 (CARTemis-1)

Multiple Myeloma; Allogeneic Stem Cell Transplantation · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

CD19-BCMA CAR-T cells infusion (CD19-BCMA CAR-T cells infusion)

Refractory Lupus Nephritis; Systemic Sclerosis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChang YingjunPhase 2

CD19-BCMA dual nanobody based CAR-T Cells (CD19-BCMA dual nanobody based CAR-T Cells)

Transplantation Candidates With Hematological Diseases · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChanghai HospitalPhase 1

CD19/BCMA CAR NK (CD19/BCMA CAR NK)

IgG4 Related Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleUnion Hospital, Tongji Medical …Phase 1

CD19/BCMA CAR-T cell therapy (CD19/BCMA CAR-T cell therapy)

Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleWest China HospitalPhase 1

CD19/BCMA in vivo CAR-T (CD19/BCMA in vivo CAR-T)

Autoimmune Diseases · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T, CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells, CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing)

Refractory Idiopathic Membranous Nephropathy · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleInstitute of Hematology & Blood…Phase 2

CM336 Plus Isatuximab (CM336 Plus Isatuximab)

Multiple Myeloma (MM); Multiple Myeloma Light Chain Induced Renal Insufficiency · Multiple Myeloma (MM)

#MultipleMyelomaMM#Antibody#Phase2#monoclonal-antibody#MultipleMyelomaLightChainInduced+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

daratumumab (Darzalex, Cyclo Thal Dex Daratumumab)

Multiple Myeloma Stage I · Multiple Myeloma Stage I

#MultipleMyelomaStageI#Antibody#Phase3#monoclonal-antibody#Janssen
Trials 1Status Active
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

3 / 5 pages

← PreviousNext →